GAITHERSBURG, Md., July 26, 2021 /PRNewswire/ — MaxCyte, Inc., (LSE: MXCT) (LSE: MXCN), a leading provider of platform technologies for cell engineering, today announced the commencement of an underwritten offering of 12,000,000 shares of common stock (the “Offering”) at an expected offering price between $11.50 and $13.50 per share. All shares to be sold in the Offering will be offered by MaxCyte. In addition, MaxCyte intends to grant the underwriters a 30-day option to purchase up to 1,800,000 additional shares of common stock.
{iframe}https://www.prnewswire.com/news-releases/maxcyte-announces-launch-of-offering-and-application-to-list-on-the-nasdaq-global-market-301340920.html{/iframe}